Literature DB >> 6437661

Current status of high linear energy transfer irradiation.

M P Richter, G E Laramore, T W Griffin, R L Goodman.   

Abstract

Based on laboratory investigations, high linear energy transfer (LET) particle irradiation is capable of more efficient cell kill than that associated with conventional or low LET irradiation. The advantages of high LET irradiation include: (1) a greater ability to damage hypoxic cells; (2) a lesser ability for repair of sublethal and potentially lethal radiation-induced damage; (3) less variation in radiation sensitivity relative to the cell cycle; and (4) a greater ability to deposit the radiation dose in the region of the tumor as opposed to the normal surrounding tissue (neutrons do not have this advantage compared to other particle therapy). Despite these laboratory advantages, it has been difficult to demonstrate any advantage of high LET irradiation in the clinic. A number of new developments have occurred to test the role of high LET: (1) sophisticated technology to enable treatment delivery with higher dose rate and improved depth dose; (2) the construction of hospital-based facilities; and (3) the development of randomized studies involving diseases in which the risk of early metastasis is minimized. It is hoped that careful study in the clinic over the next decade will elucidate the role of high LET particle therapy.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6437661     DOI: 10.1002/1097-0142(19841201)54:2+<2814::aid-cncr2820541429>3.0.co;2-g

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  2 in total

Review 1.  [Perioperative radiotherapy of bone and soft tissue tumors].

Authors:  H D Franke
Journal:  Langenbecks Arch Chir       Date:  1987

2.  Exposure to hyperbaric oxygen induces cell cycle perturbation in prostate cancer cells.

Authors:  J E Kalns; E H Piepmeier
Journal:  In Vitro Cell Dev Biol Anim       Date:  1999-02       Impact factor: 2.416

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.